Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 11
Submit an article Journal homepage
377
Views
13
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma

Haowei (Linda) SunDivision of Hematology, Department of Medicine, University of British Columbia, Vancouver, Canada;
,
Eshetu G. AtenafuDepartment of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada;
,
Richard TsangRadiation Oncology, Princess Margaret Cancer Centre, Toronto, Canada;
,
Vishal KukretiMedical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada;
,
Theodore K. MarrasDivision of Respirology, University Health Network, Toronto, Canada
,
Michael CrumpMedical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada;
&
John KuruvillaMedical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada; Correspondence[email protected]
 show all
Pages 2607-2614 | Received 29 Aug 2016, Accepted 13 Mar 2017, Published online: 15 May 2017

References

  • Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–1484.
  • Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. JCO. 2003;21:607–614.
  • Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. JCO. 1987;5:27–37.
  • Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119:692–695.
  • Martin W, Ristow K, Habermann T, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. JCO. 2005;23:7614–7620.
  • Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120:617–624.
  • Horning SJ, Adhikari A, Rizk N, et al. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol. 1994;12:297–305.
  • Matthews JH. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease: possible synergy. Lancet. 1993;342:988.
  • Ngeow J, Tan IB, Kanesvaran R, et al. Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma. Ann Hematol. 2011;90:67–72.
  • O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14:91–96.
  • Senan S, Paul J, Thomson N, et al. Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity. Eur J Cancer. 1992;28A:2084.
  • Fong D, Steurer M, Greil R, et al. Hodgkin lymphoma in Tyrol-a population-based study. Ann Hematol. 2009;88:449–456.
  • Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1861.
  • Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease: International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–1514.
  • Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.
  • Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. JCO. 1999;17:1244.
  • Canellos GP, Duggan D, Johnson J, et al. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? JCO. 2004;22:1532–1533.
  • Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007;137:545–552.
  • Minuk LA, Monkman K, Chin-Yee IH, et al. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study. Leuk Lymphoma. 2012;53:57–63.
  • McKeage MJ, Evans BD, Atkinson C, et al. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. JCO. 1990;8:779–783.
  • Eichenauer DA, Engert A, André M, ESMO Guidelines Working Group, et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:70–75.
  • Hoppe RT, Advani RH, Ai WZ, et al. NCCN Hodgkin lymphoma. J Natl Compr Canc Netw. 2011;9:1020–1058.
  • Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127:2189–2192.
  • Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374:2419–2429.
  • Ansell SM, Younes A, Connors JM, et al. Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study [abstract]. J Clin Oncol. 2014;32.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.